The latest price target for Bicara Therapeutics (NASDAQ:BCAX) was reported by Wells Fargo on November 11, 2025. The analyst firm set a price target for $11.00 expecting BCAX to fall to within 12 months (a possible -40.54% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Bicara Therapeutics (NASDAQ:BCAX) was provided by Wells Fargo, and Bicara Therapeutics maintained their equal-weight rating.

The last upgrade for Bicara Therapeutics Inc happened on May 23, 2025 when Wells Fargo raised their price target to $8. Wells Fargo previously had an underweight for Bicara Therapeutics Inc.

There is no last downgrade for Bicara Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicara Therapeutics was filed on November 11, 2025 so you should expect the next rating to be made available sometime around November 11, 2026.

While ratings are subjective and will change, the latest Bicara Therapeutics (BCAX) rating was a maintained with a price target of $8.00 to $11.00. The current price Bicara Therapeutics (BCAX) is trading at is $18.50, which is out of the analyst’s predicted range.